Top

Published in:

Open Access 01-12-2023 | Cytokines | Perspective

NRF2 and STAT3: friends or foes in carcinogenesis?

Authors: Andrea Arena, Maria Anele Romeo, Rossella Benedetti, Maria Saveria Gilardini Montani, Roberta Santarelli, Roberta Gonnella, Gabriella D’Orazi, Mara Cirone

Published in: Discover Oncology | Issue 1/2023

Abstract

NRF2 is a transcription factor that plays a pivotal role in carcinogenesis, also through the interaction with several pro-survival pathways. NRF2 controls the transcription of detoxification enzymes and a variety of other molecules impinging in several key biological processes. This perspective will focus on the complex interplay of NRF2 with STAT3, another transcription factor often aberrantly activated in cancer and driving tumorigenesis as well as immune suppression. Both NRF2 and STAT3 can be regulated by ER stress/UPR activation and their cross-talk influences and is influenced by autophagy and cytokines, contributing to shape the microenvironment, and both control the execution of DDR, also by regulating the expression of HSPs. Given the importance of these transcription factors, more investigations aimed at better elucidating the outcome of their networking could help to discover new and more efficacious strategies to fight cancer.

Tonelli C, Chio IIC, Tuveson DA. Transcriptional regulation by Nrf2. Antioxid Redox Signal. 2018;29(17):1727–45. https://doi.org/10.1089/ars.2017.7342.CrossRefPubMedPubMedCentral

Kim J, Keum YS. NRF2, a key regulator of antioxidants with two faces towards cancer. Oxid Med Cell Longev. 2016;2016:2746457. https://doi.org/10.1155/2016/2746457.CrossRefPubMedPubMedCentral

Furukawa M, Xiong Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol. 2005;25(1):162–71. https://doi.org/10.1128/MCB.25.1.162-171.2005.CrossRefPubMedPubMedCentral

Bellezza I, Giambanco I, Minelli A, Donato R. Nrf2-Keap1 signaling in oxidative and reductive stress. Biochim Biophys Acta Mol Cell Res. 2018;1865(5):721–33. https://doi.org/10.1016/j.bbamcr.2018.02.010.CrossRefPubMed

Katsuragi Y, Ichimura Y, Komatsu M. Regulation of the Keap1–Nrf2 pathway by p62/SQSTM1. Current Opin Toxicol. 2016;1:54–61. https://doi.org/10.1016/j.cotox.2016.09.005.CrossRef

Jiang T, Harder B, Rojo de la Vega M, Wong PK, Chapman E, Zhang DD. p62 links autophagy and Nrf2 signaling. Free Radic Biol Med. 2015;88(Pt B):199–204. https://doi.org/10.1016/j.freeradbiomed.2015.06.014.CrossRefPubMedPubMedCentral

Hawkins WD, Grush ER, Klionsky DJ. The world’s first (and probably last) autophagy video game. Autophagy. 2023;19(1):352–7. https://doi.org/10.1080/15548627.2022.2143212.CrossRefPubMed

Ahuja M, Kaidery NA, Dutta D, Attucks OC, Kazakov EH, Gazaryan I, et al. Harnessing the therapeutic potential of the Nrf2/Bach1 signaling pathway in Parkinson’s disease. Antioxidants (Basel). 2022. https://doi.org/10.3390/antiox11091780.CrossRefPubMed

Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234–48. https://doi.org/10.1038/nrclinonc.2018.8.CrossRefPubMedPubMedCentral

10.

Tolomeo M, Cavalli A, Cascio A. STAT1 and Its crucial role in the control of viral infections. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms23084095.CrossRefPubMedPubMedCentral

11.

Verhoeven Y, Tilborghs S, Jacobs J, De Waele J, Quatannens D, Deben C, et al. The potential and controversy of targeting STAT family members in cancer. Semin Cancer Biol. 2020;60:41–56. https://doi.org/10.1016/j.semcancer.2019.10.002.CrossRefPubMed

12.

Lee H, Jeong AJ, Ye SK. Highlighted STAT3 as a potential drug target for cancer therapy. BMB Rep. 2019;52(7):415–23. https://doi.org/10.5483/BMBRep.2019.52.7.152.CrossRefPubMedPubMedCentral

13.

Awasthi N, Liongue C, Ward AC. STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer. J Hematol Oncol. 2021;14(1):198. https://doi.org/10.1186/s13045-021-01214-y.CrossRefPubMedPubMedCentral

14.

Tolomeo M, Cascio A. The multifaced role of STAT3 in cancer and its implication for anticancer therapy. Int J Mol Sci. 2021. https://doi.org/10.3390/ijms22020603.CrossRefPubMedPubMedCentral

15.

Cirone M. Cancer cells dysregulate PI3K/AKT/mTOR pathway activation to ensure their survival and proliferation: mimicking them is a smart strategy of gammaherpesviruses. Crit Rev Biochem Mol Biol. 2021;56(5):500–9. https://doi.org/10.1080/10409238.2021.1934811.CrossRefPubMed

16.

Xu J, Zhang J, Mao QF, Wu J, Wang Y. The interaction between autophagy and JAK/STAT3 signaling pathway in tumors. Front Genet. 2022;13:880359. https://doi.org/10.3389/fgene.2022.880359.CrossRefPubMedPubMedCentral

17.

Shen S, Niso-Santano M, Adjemian S, Takehara T, Malik SA, Minoux H, et al. Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity. Mol Cell. 2012;48(5):667–80. https://doi.org/10.1016/j.molcel.2012.09.013.CrossRefPubMed

18.

Dutta P, Zhang L, Zhang H, Peng Q, Montgrain PR, Wang Y, et al. Unphosphorylated STAT3 in heterochromatin formation and tumor suppression in lung cancer. BMC Cancer. 2020;20(1):145. https://doi.org/10.1186/s12885-020-6649-2.CrossRefPubMedPubMedCentral

19.

Huang J, Brumell JH. Bacteria-autophagy interplay: a battle for survival. Nat Rev Microbiol. 2014;12(2):101–14. https://doi.org/10.1038/nrmicro3160.CrossRefPubMedPubMedCentral

20.

Choi Y, Bowman JW, Jung JU. Autophagy during viral infection - a double-edged sword. Nat Rev Microbiol. 2018;16(6):341–54. https://doi.org/10.1038/s41579-018-0003-6.CrossRefPubMedPubMedCentral

21.

Granato M, Lacconi V, Peddis M, Di Renzo L, Valia S, Rivanera D, et al. Hepatitis C virus present in the sera of infected patients interferes with the autophagic process of monocytes impairing their in-vitro differentiation into dendritic cells. Biochim Biophys Acta. 2014;1843(7):1348–55. https://doi.org/10.1016/j.bbamcr.2014.04.003.CrossRefPubMed

22.

Cirone M. EBV and KSHV infection dysregulates autophagy to optimize viral replication prevent immune recognition and promote tumorigenesis. Viruses. 2018. https://doi.org/10.3390/v10110599.CrossRefPubMedPubMedCentral

23.

Granato M, Gilardini Montani MS, Zompetta C, Santarelli R, Gonnella R, Romeo MA, et al. Quercetin interrupts the positive feedback loop between STAT3 and IL-6, promotes autophagy, and reduces ROS, preventing EBV-Driven B cell immortalization. Biomolecules. 2019. https://doi.org/10.3390/biom9090482.CrossRefPubMedPubMedCentral

24.

Santarelli R, Arteni AMB, Gilardini Montani MS, Romeo MA, Gaeta A, Gonnella R, et al. KSHV dysregulates bulk macroautophagy, mitophagy and UPR to promote endothelial to mesenchymal transition and CCL2 release, key events in viral-driven sarcomagenesis. Int J Cancer. 2020;147(12):3500–10. https://doi.org/10.1002/ijc.33163.CrossRefPubMed

25.

Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, et al. Autophagy in malignant transformation and cancer progression. EMBO J. 2015;34(7):856–80. https://doi.org/10.15252/embj.201490784.CrossRefPubMedPubMedCentral

26.

Sharma V, Verma S, Seranova E, Sarkar S, Kumar D. Selective autophagy and xenophagy in infection and disease. Front Cell Dev Biol. 2018;6:147. https://doi.org/10.3389/fcell.2018.00147.CrossRefPubMedPubMedCentral

27.

Zhang Y, Morgan MJ, Chen K, Choksi S, Liu ZG. Induction of autophagy is essential for monocyte-macrophage differentiation. Blood. 2012;119(12):2895–905. https://doi.org/10.1182/blood-2011-08-372383.CrossRefPubMedPubMedCentral

28.

Granato M, Santarelli R, Farina A, Gonnella R, Lotti LV, Faggioni A, et al. Epstein-barr virus blocks the autophagic flux and appropriates the autophagic machinery to enhance viral replication. J Virol. 2014;88(21):12715–26. https://doi.org/10.1128/JVI.02199-14.CrossRefPubMedPubMedCentral

29.

Granato M, Santarelli R, Filardi M, Gonnella R, Farina A, Torrisi MR, et al. The activation of KSHV lytic cycle blocks autophagy in PEL cells. Autophagy. 2015;11(11):1978–86. https://doi.org/10.1080/15548627.2015.1091911.CrossRefPubMedPubMedCentral

30.

Cirone M, D’Orazi G. NRF2 in cancer: cross-talk with oncogenic pathways and involvement in Gammaherpesvirus-driven carcinogenesis. Int J Mol Sci. 2022. https://doi.org/10.3390/ijms24010595.CrossRefPubMedPubMedCentral

31.

Gilardini Montani MS, Falcinelli L, Santarelli R, Romeo MA, Granato M, Faggioni A, et al. Kaposi Sarcoma Herpes Virus (KSHV) infection inhibits macrophage formation and survival by counteracting macrophage colony-stimulating factor (M-CSF)-induced increase of Reactive Oxygen Species (ROS), c-Jun N-terminal kinase (JNK) phosphorylation and autophagy. Int J Biochem Cell Biol. 2019;114:105560. https://doi.org/10.1016/j.biocel.2019.06.008.CrossRefPubMed

32.

Gilardini Montani MS, Santarelli R, Granato M, Gonnella R, Torrisi MR, Faggioni A, et al. EBV reduces autophagy, intracellular ROS and mitochondria to impair monocyte survival and differentiation. Autophagy. 2019;15(4):652–67. https://doi.org/10.1080/15548627.2018.1536530.CrossRefPubMed

33.

Bendavit G, Aboulkassim T, Hilmi K, Shah S, Batist G. Nrf2 Transcription Factor Can Directly Regulate mTOR: LINKING CYTOPROTECTIVE GENE EXPRESSION TO A MAJOR METABOLIC REGULATOR THAT GENERATES REDOX ACTIVITY. J Biol Chem. 2016;291(49):25476–88. https://doi.org/10.1074/jbc.M116.760249.CrossRefPubMedPubMedCentral

34.

Gong H, Tai H, Huang N, Xiao P, Mo C, Wang X, et al. Nrf2-SHP cascade-mediated STAT3 inactivation contributes to AMPK-driven protection against endotoxic inflammation. Front Immunol. 2020;11:414. https://doi.org/10.3389/fimmu.2020.00414.CrossRefPubMedPubMedCentral

35.

Papp D, Lenti K, Modos D, Fazekas D, Dul Z, Turei D, et al. The NRF2-related interactome and regulome contain multifunctional proteins and fine-tuned autoregulatory loops. FEBS Lett. 2012;586(13):1795–802. https://doi.org/10.1016/j.febslet.2012.05.016.CrossRefPubMedPubMedCentral

36.

Ju KD, Lim JW, Kim H. Peroxisome proliferator-activated receptor-gamma inhibits the activation of STAT3 in cerulein-stimulated pancreatic acinar cells. J Cancer Prev. 2017;22(3):189–94. https://doi.org/10.15430/JCP.2017.22.3.189.CrossRefPubMedPubMedCentral

37.

Ahmed SM, Luo L, Namani A, Wang XJ, Tang X. Nrf2 signaling pathway: pivotal roles in inflammation. Biochim Biophys Acta Mol Basis Dis. 2017;1863(2):585–97. https://doi.org/10.1016/j.bbadis.2016.11.005.CrossRefPubMed

38.

Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41. https://doi.org/10.1016/j.immuni.2019.06.025.CrossRefPubMedPubMedCentral

39.

Gilardini Montani MS, Tarquini G, Santarelli R, Gonnella R, Romeo MA, Benedetti R, et al. p62/SQSTM1 promotes mitophagy and activates the NRF2-mediated antioxidant and anti-inflammatory response restraining EBV-driven B lymphocyte proliferation. Carcinogenesis. 2022;43(3):277–87. https://doi.org/10.1093/carcin/bgab116.CrossRefPubMed

40.

Liu H, Feng XD, Yang B, Tong RL, Lu YJ, Chen DY, et al. Dimethyl fumarate suppresses hepatocellular carcinoma progression via activating SOCS3/JAK1/STAT3 signaling pathway. Am J Transl Res. 2019;11(8):4713–25.PubMedPubMedCentral

41.

Gonnella R, Zarrella R, Santarelli R, Germano CA, Gilardini Montani MS, Cirone M. Mechanisms of sensitivity and resistance of primary effusion lymphoma to dimethyl fumarate (DMF). Int J Mol Sci. 2022. https://doi.org/10.3390/ijms23126773.CrossRefPubMedPubMedCentral

42.

Lee JH, Rangappa S, Mohan CD, Basappa Sethi G, Lin ZX, et al. Brusatol, a Nrf2 inhibitor targets STAT3 signaling cascade in head and neck squamous cell carcinoma. Biomolecules. 2019. https://doi.org/10.3390/biom9100550.CrossRefPubMedPubMedCentral

43.

Tian Y, Liu H, Wang M, Wang R, Yi G, Zhang M, et al. Role of STAT3 and NRF2 in tumors: potential targets for antitumor therapy. Molecules. 2022. https://doi.org/10.3390/molecules27248768.CrossRefPubMedPubMedCentral

44.

Cai SJ, Liu Y, Han S, Yang C. Brusatol, an NRF2 inhibitor for future cancer therapeutic. Cell Biosci. 2019;9:45. https://doi.org/10.1186/s13578-019-0309-8.CrossRefPubMedPubMedCentral

45.

Granato M, Chiozzi B, Filardi MR, Lotti LV, Di Renzo L, Faggioni A, et al. Tyrosine kinase inhibitor tyrphostin AG490 triggers both apoptosis and autophagy by reducing HSF1 and Mcl-1 in PEL cells. Cancer Lett. 2015;366(2):191–7. https://doi.org/10.1016/j.canlet.2015.07.006.CrossRefPubMed

46.

Cirone M, Di Renzo L, Lotti LV, Conte V, Trivedi P, Santarelli R, et al. Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91. PLoS ONE. 2012;7(3):e31732. https://doi.org/10.1371/journal.pone.0031732.CrossRefPubMedPubMedCentral

47.

Gargalionis AN, Papavassiliou KA, Papavassiliou AG. Targeting STAT3 signaling pathway in colorectal cancer. Biomedicines. 2021. https://doi.org/10.3390/biomedicines9081016.CrossRefPubMedPubMedCentral

48.

McFarland BC, Hong SW, Rajbhandari R, Twitty GB Jr, Gray GK, Yu H, et al. NF-kappaB-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma. PLoS ONE. 2013;8(11):e78728. https://doi.org/10.1371/journal.pone.0078728.CrossRefPubMedPubMedCentral

49.

Zhao G, Zhu G, Huang Y, Zheng W, Hua J, Yang S, et al. IL-6 mediates the signal pathway of JAK-STAT3-VEGF-C promoting growth, invasion and lymphangiogenesis in gastric cancer. Oncol Rep. 2016;35(3):1787–95. https://doi.org/10.3892/or.2016.4544.CrossRefPubMed

50.

Resemann HK, Watson CJ, Lloyd-Lewis B. The Stat3 paradox: a killer and an oncogene. Mol Cell Endocrinol. 2014;382(1):603–11. https://doi.org/10.1016/j.mce.2013.06.029.CrossRefPubMed

51.

Zhang L, Badgwell DB, Bevers JJ 3rd, Schlessinger K, Murray PJ, Levy DE, et al. IL-6 signaling via the STAT3/SOCS3 pathway: functional analysis of the conserved STAT3 N-domain. Mol Cell Biochem. 2006;288(1–2):179–89. https://doi.org/10.1007/s11010-006-9137-3.CrossRefPubMedPubMedCentral

52.

Lu C, Xu W, Shao J, Zhang F, Chen A, Zheng S. Nrf2 induces lipocyte phenotype via a SOCS3-dependent negative feedback loop on JAK2/STAT3 signaling in hepatic stellate cells. Int Immunopharmacol. 2017;49:203–11. https://doi.org/10.1016/j.intimp.2017.06.001.CrossRefPubMed

53.

Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016;37(9):11553–72. https://doi.org/10.1007/s13277-016-5098-7.CrossRefPubMed

54.

Kim SJ, Saeidi S, Cho NC, Kim SH, Lee HB, Han W, et al. Interaction of Nrf2 with dimeric STAT3 induces IL-23 expression: Implications for breast cancer progression. Cancer Lett. 2021;500:147–60. https://doi.org/10.1016/j.canlet.2020.11.047.CrossRefPubMed

55.

Santarelli R, Gonnella R, Di Giovenale G, Cuomo L, Capobianchi A, Granato M, et al. STAT3 activation by KSHV correlates with IL-10, IL-6 and IL-23 release and an autophagic block in dendritic cells. Sci Rep. 2014;4:4241. https://doi.org/10.1038/srep04241.CrossRefPubMedPubMedCentral

56.

Wu X, Tao P, Zhou Q, Li J, Yu Z, Wang X, et al. IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway. Oncotarget. 2017;8(13):20741–50. https://doi.org/10.18632/oncotarget.15119.CrossRefPubMedPubMedCentral

57.

Thongchot S, Vidoni C, Ferraresi A, Loilome W, Khuntikeo N, Sangkhamanon S, et al. Cancer-Associated fibroblast-derived IL-6 determines unfavorable prognosis in cholangiocarcinoma by affecting autophagy-associated chemoresponse. Cancers (Basel). 2021. https://doi.org/10.3390/cancers13092134.CrossRefPubMed

58.

Liu T, Lv YF, Zhao JL, You QD, Jiang ZY. Regulation of Nrf2 by phosphorylation: consequences for biological function and therapeutic implications. Free Radic Biol Med. 2021;168:129–41. https://doi.org/10.1016/j.freeradbiomed.2021.03.034.CrossRefPubMed

59.

Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, Diehl JA. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol. 2003;23(20):7198–209. https://doi.org/10.1128/MCB.23.20.7198-7209.2003.CrossRefPubMedPubMedCentral

60.

Meares GP, Liu Y, Rajbhandari R, Qin H, Nozell SE, Mobley JA, et al. PERK-dependent activation of JAK1 and STAT3 contributes to endoplasmic reticulum stress-induced inflammation. Mol Cell Biol. 2014;34(20):3911–25. https://doi.org/10.1128/MCB.00980-14.CrossRefPubMedPubMedCentral

61.

Liu X, Li H, Liu L, Lu Y, Gao Y, Geng P, et al. Methylation of arginine by PRMT1 regulates Nrf2 transcriptional activity during the antioxidative response. Biochim Biophys Acta. 2016;1863(8):2093–103. https://doi.org/10.1016/j.bbamcr.2016.05.009.CrossRefPubMed

62.

McCord JM, Gao B, Hybertson BM. The complex genetic and epigenetic regulation of the Nrf2 pathways: a review. Antioxidants (Basel). 2023. https://doi.org/10.3390/antiox12020366.CrossRefPubMed

63.

Yang J, Huang J, Dasgupta M, Sears N, Miyagi M, Wang B, et al. Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc Natl Acad Sci U S A. 2010;107(50):21499–504. https://doi.org/10.1073/pnas.1016147107.CrossRefPubMedPubMedCentral

64.

Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell. 2013;23(6):839–52. https://doi.org/10.1016/j.ccr.2013.04.008.CrossRefPubMedPubMedCentral

65.

Dasgupta M, Dermawan JK, Willard B, Stark GR. STAT3-driven transcription depends upon the dimethylation of K49 by EZH2. Proc Natl Acad Sci U S A. 2015;112(13):3985–90. https://doi.org/10.1073/pnas.1503152112.CrossRefPubMedPubMedCentral

66.

Huang L, Hu B, Ni J, Wu J, Jiang W, Chen C, et al. Transcriptional repression of SOCS3 mediated by IL-6/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasis. J Exp Clin Cancer Res. 2016;35:27. https://doi.org/10.1186/s13046-016-0301-7.CrossRefPubMedPubMedCentral

67.

Lee H, Zhang P, Herrmann A, Yang C, Xin H, Wang Z, et al. Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci U S A. 2012;109(20):7765–9. https://doi.org/10.1073/pnas.1205132109.CrossRefPubMedPubMedCentral

68.

Cao H, Wang L, Chen B, Zheng P, He Y, Ding Y, et al. DNA demethylation upregulated Nrf2 expression in Alzheimer’s disease cellular model. Front Aging Neurosci. 2015;7:244. https://doi.org/10.3389/fnagi.2015.00244.CrossRefPubMed

69.

Taheri Z, Asadzadeh Aghdaei H, Irani S, Modarressi MH, Zahra N. Evaluation of the epigenetic demethylation of NRF2, a master transcription factor for antioxidant enzymes. Colorectal Cancer Rep Biochem Mol Biol. 2020;9(1):33–9. https://doi.org/10.29252/rbmb.9.1.33.CrossRefPubMed

70.

Zhou JW, Wang M, Sun NX, Qing Y, Yin TF, Li C, et al. Sulforaphane-induced epigenetic regulation of Nrf2 expression by DNA methyltransferase in human Caco-2 cells. Oncol Lett. 2019;18(3):2639–47. https://doi.org/10.3892/ol.2019.10569.CrossRefPubMedPubMedCentral

71.

Al-Jamal HA, Mat Jusoh SA, Hassan R, Johan MF. Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia. BMC Cancer. 2015;15:869. https://doi.org/10.1186/s12885-015-1695-x.CrossRefPubMedPubMedCentral

72.

Sottile ML, Nadin SB. Heat shock proteins and DNA repair mechanisms: an updated overview. Cell Stress Chaperones. 2018;23(3):303–15. https://doi.org/10.1007/s12192-017-0843-4.CrossRefPubMed

73.

Donati YR, Slosman DO, Polla BS. Oxidative injury and the heat shock response. Biochem Pharmacol. 1990;40(12):2571–7. https://doi.org/10.1016/0006-2952(90)90573-4.CrossRefPubMed

74.

Dayalan Naidu S, Kostov RV, Dinkova-Kostova AT. Transcription factors Hsf1 and Nrf2 engage in crosstalk for cytoprotection. Trends Pharmacol Sci. 2015;36(1):6–14. https://doi.org/10.1016/j.tips.2014.10.011.CrossRefPubMed

75.

Khalil HS, Deeni Y. NRF2 inhibition causes repression of ATM and ATR expression leading to aberrant DNA damage response. BioDiscovery. 2015. https://doi.org/10.7750/BioDiscovery.2015.15.1.CrossRef

76.

Jego G, Hermetet F, Girodon F, Garrido C. Chaperoning STAT3/5 by heat shock proteins: interest of their targeting in cancer therapy. Cancers (Basel). 2019. https://doi.org/10.3390/cancers12010021.CrossRefPubMed

77.

Niu G, Wright KL, Ma Y, Wright GM, Huang M, Irby R, et al. Role of Stat3 in regulating p53 expression and function. Mol Cell Biol. 2005;25(17):7432–40. https://doi.org/10.1128/MCB.25.17.7432-7440.2005.CrossRefPubMedPubMedCentral

78.

Granato M, Gilardini Montani MS, Santarelli R, D’Orazi G, Faggioni A, Cirone M. Apigenin, by activating p53 and inhibiting STAT3, modulates the balance between pro-apoptotic and pro-survival pathways to induce PEL cell death. J Exp Clin Cancer Res. 2017;36(1):167. https://doi.org/10.1186/s13046-017-0632-z.CrossRefPubMedPubMedCentral

79.

Garufi A, Baldari S, Pettinari R, Gilardini Montani MS, D’Orazi V, Pistritto G, et al. A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status. J Exp Clin Cancer Res. 2020;39(1):122. https://doi.org/10.1186/s13046-020-01628-5.CrossRefPubMedPubMedCentral

80.

Lin J, Tang H, Jin X, Jia G, Hsieh JT. p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3. Oncogene. 2002;21(19):3082–8. https://doi.org/10.1038/sj.onc.1205426.CrossRefPubMed

81.

Faraonio R, Vergara P, Di Marzo D, Pierantoni MG, Napolitano M, Russo T, et al. p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. J Biol Chem. 2006;281(52):39776–84. https://doi.org/10.1074/jbc.M605707200.CrossRefPubMed

82.

Lisek K, Campaner E, Ciani Y, Walerych D, Del Sal G. Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells. Oncotarget. 2018;9(29):20508–23. https://doi.org/10.18632/oncotarget.24974.CrossRefPubMedPubMedCentral

83.

Romeo MA, Gilardini Montani MS, Benedetti R, Santarelli R, D’Orazi G, Cirone M. STAT3 and mutp53 engage a positive feedback loop involving HSP90 and the mevalonate pathway. Front Oncol. 2020;10:1102. https://doi.org/10.3389/fonc.2020.01102.CrossRefPubMedPubMedCentral

84.

Schulz-Heddergott R, Stark N, Edmunds SJ, Li J, Conradi LC, Bohnenberger H, et al. Therapeutic ablation of gain-of-function mutant p53 in colorectal cancer inhibits Stat3-mediated tumor growth and invasion. Cancer Cell. 2018;34(2):298–314. https://doi.org/10.1016/j.ccell.2018.07.004.CrossRefPubMedPubMedCentral

85.

Turei D, Papp D, Fazekas D, Foldvari-Nagy L, Modos D, Lenti K, et al. NRF2-ome: an integrated web resource to discover protein interaction and regulatory networks of NRF2. Oxid Med Cell Longev. 2013;2013:737591. https://doi.org/10.1155/2013/737591.CrossRefPubMedPubMedCentral

86.

Laudisi F, Cherubini F, Monteleone G, Stolfi C. STAT3 interactors as potential therapeutic targets for cancer treatment. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19061787.CrossRefPubMedPubMedCentral

Title: NRF2 and STAT3: friends or foes in carcinogenesis?
Authors: Andrea Arena
Maria Anele Romeo
Rossella Benedetti
Maria Saveria Gilardini Montani
Roberta Santarelli
Roberta Gonnella
Gabriella D’Orazi
Mara Cirone
Publication date: 01-12-2023
Publisher: Springer US
Keywords: Cytokines
Kaposi's Sarcoma-Associated Herpesvirus
Published in: Discover Oncology / Issue 1/2023
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-023-00644-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Resection margins, lymph node harvest and 3 year survival in open and laparoscopic colorectal cancer surgery; a prospective cohort study

Identification of hepatocellular carcinoma-related subtypes and development of a prognostic model: a study based on ferritinophagy-related genes

The immunomodulatory function and antitumor effect of disulfiram: paving the way for novel cancer therapeutics

Evaluation of the relationship between Ki67 expression level and neoadjuvant treatment response and prognosis in breast cancer based on the Neo-Bioscore staging system

ELFN1-AS1 promotes GDF15-mediated immune escape of colorectal cancer from NK cells by facilitating GCN5 and SND1 association

Empagliflozin: a potential anticancer drug

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials